Opus Genetics reports FY2025 net loss $49.6M; cash $70.1M; PDUFA date Oct 2026

Opus Genetics, Inc.

Net loss $49.6M ($0.80/sh) vs $57.5M ($2.15/sh) in 2024; revenue $14.2M from Viatris collab.
Cash $45.1M at Dec 31, 2025; raised $25M in private placement to $70.1M; runway into H1 2028.
BEST1 gene therapy: sentinel patient showed 12-letter BCVA gain and 23% CST decrease; three-month data from full cohort expected mid-2026.
FDA set PDUFA date Oct 17, 2026 for Phentolamine Ophthalmic Solution 0.75% for presbyopia.
Phase 3 LCA5 trial enrolling; RDEP review submission planned Q1 2026; MERTK funding secured from Abu Dhabi fund.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Opus Genetics, Inc. reported the year ended December 31, 2025 results: revenue $14.2 million.

Period: the year ended December 31, 2025
Revenue: $14.2 million
Result: reported results

Exact text from the filing

Revenue : License and collaborations revenue totaled $14.2 million for the year ended December 31, 2025, compared to $11.0 million for the same period in 2024.

View on SEC.gov

31 earnings releases filed in the last 30 days. Browse all earnings releases →

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-26-008621

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.